A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives
Standard
A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. / Agha, A; Schlüter, H; König, S; Biel, K; Tepel, M; Zidek, W.
In: J VASC RES, Vol. 29, No. 3, 01.05.1992, p. 281-9.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives
AU - Agha, A
AU - Schlüter, H
AU - König, S
AU - Biel, K
AU - Tepel, M
AU - Zidek, W
PY - 1992/5/1
Y1 - 1992/5/1
N2 - Platelet homogenates from 200 ml blood of essential hypertensives (n = 28) and normotensives (n = 13) were deproteinized and separated by gel chromatography. The fractions obtained were then tested for vasopressor activity in the isolated perfused rat kidney. In both normotensives and hypertensives, two vasopressor fractions appeared. There was no difference in vasopressor activity in the first vasoactive fraction between normotensives and hypertensives. In the second vasoactive fraction, the hypertensive patients showed a significant higher activity than the normotensive subjects (increase in perfusion pressure by 35.9 +/- 11.5 vs. 6.8 +/- 5.3 mmHg, p less than 0.01). This vasopressor fraction was not inhibited by saralasin, phentolamine, ketanserin, nitroprusside and daltroban and was effective after pretreatment with indomethacin and reserpine and in enzymatically deendothelialized kidneys. The effect was reduced by nifedipine and unchanged by heating the fraction at 100 degrees C and by incubation with proteinase K. It is concluded that a yet unidentified platelet-derived vasopressor agent may contribute to the enhanced vasoconstriction in essential hypertension.
AB - Platelet homogenates from 200 ml blood of essential hypertensives (n = 28) and normotensives (n = 13) were deproteinized and separated by gel chromatography. The fractions obtained were then tested for vasopressor activity in the isolated perfused rat kidney. In both normotensives and hypertensives, two vasopressor fractions appeared. There was no difference in vasopressor activity in the first vasoactive fraction between normotensives and hypertensives. In the second vasoactive fraction, the hypertensive patients showed a significant higher activity than the normotensive subjects (increase in perfusion pressure by 35.9 +/- 11.5 vs. 6.8 +/- 5.3 mmHg, p less than 0.01). This vasopressor fraction was not inhibited by saralasin, phentolamine, ketanserin, nitroprusside and daltroban and was effective after pretreatment with indomethacin and reserpine and in enzymatically deendothelialized kidneys. The effect was reduced by nifedipine and unchanged by heating the fraction at 100 degrees C and by incubation with proteinase K. It is concluded that a yet unidentified platelet-derived vasopressor agent may contribute to the enhanced vasoconstriction in essential hypertension.
KW - Adenosine Triphosphate
KW - Adult
KW - Angiotensin II
KW - Animals
KW - Blood Platelets
KW - Blood Pressure
KW - Chromatography, Gel
KW - Female
KW - Humans
KW - Hypertension
KW - In Vitro Techniques
KW - Male
KW - Middle Aged
KW - Norepinephrine
KW - Rats
KW - Rats, Inbred WKY
KW - Reference Values
KW - Renal Circulation
KW - Serotonin
KW - Sodium-Potassium-Exchanging ATPase
KW - Tissue Extracts
KW - Vasoconstrictor Agents
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1159/000158943
DO - 10.1159/000158943
M3 - SCORING: Journal article
C2 - 1324015
VL - 29
SP - 281
EP - 289
IS - 3
ER -
